S100A6 Antibody (YA674)

S100A6 (calcyclin) is a member of the S100 calcium-binding protein family and contains two EF-hand calcium-binding motifs that enable calcium-dependent conformational changes and interactions with numerous target proteins involved in cellular signaling^[1][2]. Upon Ca²⁺ binding, S100A6 exposes hydrophobic surfaces that facilitate interactions with proteins located in the cytoplasm, nucleus, cell membrane, and extracellular environment, thereby contributing to cytoskeletal regulation, signal transduction, cellular stress responses, proliferation, and differentiation^[2][3]. Mechanistically, S100A6 participates in the regulation of cell-cycle progression and cytoskeletal dynamics through interactions with multiple binding partners, and its expression is preferentially induced when quiescent cells re-enter proliferation^[3][4]. In disease contexts, aberrant S100A6 expression has been reported in numerous malignancies, including melanoma, lung, colorectal, pancreatic, liver, and thyroid cancers, supporting its relevance as a disease-associated biomarker and experimental target^[2][5]. S100A6 is also implicated in non-neoplastic disorders, including nervous system, cardiovascular, and musculoskeletal diseases, indicating broad biological significance beyond tumor biology^[2]. Compared with related S100 family isoforms, S100A6 exhibits distinct calcium-dependent interaction networks and subcellular localization patterns, including association with the plasma membrane and nuclear envelope following calcium activation^[1][2]. For experimental applications, S100A6 is widely studied as a calcium-responsive regulatory protein and biomarker candidate; however, the retrieved literature does not provide well-established selective agonists or inhibitors suitable for routine research use^[1][2].